使用Endurant平台医师改良腔内移植物修复不可延期复杂腹主动脉瘤:模板与初步结果
该回顾性分析纳入2021至2024年连续18例不适合其他技术或定制器械的复杂腹主动脉瘤患者,使用基于Endurant平台的医师改良腔内移植物(PMEG)修复37条目标血管。技术成功17例(94%),无30天死亡、无再干预,中位随访10个月靶血管通畅率100%。作者认为该技术短期安全有效,但需长期数据及标准化方案的前瞻性研究。
要点
- 18例复杂AAA患者使用Endurant平台PMEG,技术成功17例(94%),无30天死亡及再干预。
- 中位随访10个月靶血管通畅率100%,3例(16.7%)死于非主动脉相关原因。
- 作者建议需长期数据及标准化方案的前瞻性研究以与定制器械比较。
核心结论
- 使用Medtronic Endurant腔内移植物、辅以二维模板和3D打印确认模型的PMEG,为复杂、不可延期AAA修复提供了安全有效的短期结果。
- 作者认为需长期数据及采用标准化方案的PMEG前瞻性研究,以积累证据并与定制器械和即用型器械进行充分比较。
研究设计与样本
- 回顾性分析连续纳入的18例不适合其他技术或定制器械的患者,于2021至2024年间使用PMEG Endurant进行修复。
- 开发Endurant腔内移植物的二维模板以确保开窗位置精确,术中通过3D打印主动脉模板确认。
主要发现
- 18例患者(平均年龄79.4±9岁,94%男性)共37条目标血管,使用Endurant主体(n=10,55.6%)、腹部管状移植物(n=4,22.2%)或主动脉延伸段(n=4,22.2%)。
- 平均动脉瘤直径70.0±23 mm,平均开窗数2.1±1(33.3%为3开窗或4开窗),平均植入时间198.9±90分钟。
- 最常用桥接支架为iCover(n=15,40.5%)、BeGraft(n=10,27.0%)和VBX(n=9,24.3%)。
- 除1例外技术成功(n=17,94%),无30天死亡、无再干预,中位随访10个月靶血管通畅率100%。
- 3例(16.7%)死于非主动脉相关原因;1例残留IA型内漏在CT随访中观察到,根据患者决定未予治疗。
局限性
- 作者指出需长期数据及采用标准化方案的PMEG前瞻性研究,以积累证据并与定制器械和即用型器械进行充分比较。
- 本报告为短期结果(中位随访10个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVES: Complex abdominal aortic aneurysm (AAA) repair often requires the use of fenestrated and branched endografts, which can be influenced by factors such as device availability, cost, and operator expertise. This study aims to evaluate the preliminary results with physician-modified endografts (PMEGs) utilizing the Medtronic Endurant platform. METHODS: Retrospective analysis of consecutive patients unsuitable for other techniques or custom-made devices, in which a PMEG Endurant was used for repair between 2021 and 2024. Bidimensional templates of the Endurant endograft were developed to ensure precise fenestration placement, which was confirmed intraoperatively with a 3D-printed aortic template. Endpoints were technical success, mortality, reinterventions, and target vessel patency. RESULTS: Thirty-seven target vessels in 18 patients (mean age 79.4 ± 9 years, 94% male) were treated with Endurant main bodies (n=10, 55.6%), abdominal tubes (n=4, 22.2%), or aortic extensions (n=4, 22.2%). Mean aneurysm diameter was 70.0 ± 23 mm. Mean number of fenestrations was 2.1 ± 1 (33.3% 3-FEN or 4-FEN). The most frequent bridging stents were iCover (n=15, 40.5%), BeGraft (n=10, 27.0%), and VBX (n=9, 24.3%). Mean implantation time was 198.9 ± 90 minutes. Technical success was achieved in all but one case (n=17, 94%), with no 30 day mortality, no reinterventions, and 100% target vessel patency at a median follow-up of 10 months. Three patients (16.7%) died of non aortic-related causes. One residual type IA endoleak was adverted in computed tomography scan controls and was left untreated according to patient's decision. CONCLUSION: PMEG utilizing the Medtronic Endurant endograft, supported by bidimensional templates and 3D-printed confirmation models, provided safe and effective short-term outcomes for complex, non-deferrable AAA repair. Long-term data and a prospective study on PMEG with a standardized protocol would allow for evidence to arise on this technique, facilitating adequate comparisons with custom-made and off-the-shelf devices. CLINICAL IMPACT: This short series highlights the initial outcomes of physician-modified endografts (PMEG) using the Medtronic Endurant platform. Dedicated 2D templates for all Endurant sizes are provided as supplementary material, offering valuable assistance to practitioners in the vascular community. A standardized modification protocol, based on these templates along with the double-check of a sterile 3D-printed model, has allowed to achieve satisfactory short term outcomes. These outcomes are comparable to those of custom-made devices, even in scenarios requiring non-deferrable repairs and involving challenging anatomic constraints, such as type 1A endoleaks.
引用
- Álvarez Marcos F, Reyes Valdivia A, De Blas Bravo M, et al. Physician-Modified Endografts for Non-deferrable Complex Abdominal Aortic Aneurysm Repair Using the Endurant Platform: Templates and Initial Results. J Endovasc Ther. 2025. PMID: 39981832. doi:10.1177/15266028251318952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。